124 related articles for article (PubMed ID: 27197061)
21. A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer.
Suenaga M; Mizunuma N; Matsusaka S; Shinozaki E; Ozaka M; Ogura M; Chin K; Yamaguchi T
Drug Des Devel Ther; 2015; 9():1653-62. PubMed ID: 25834402
[TBL] [Abstract][Full Text] [Related]
22. Effect of irinotecan on the phenotype of peripheral blood leukocyte populations in patients with metastatic colorectal cancer.
Melichar B; Touskova M; Vesely P
Hepatogastroenterology; 2002; 49(46):967-70. PubMed ID: 12143255
[TBL] [Abstract][Full Text] [Related]
23. Tumor infiltration by T lymphocytes expressing chemokine receptor 7 (CCR7) is predictive of favorable outcome in patients with advanced colorectal carcinoma.
Correale P; Rotundo MS; Botta C; Del Vecchio MT; Ginanneschi C; Licchetta A; Conca R; Apollinari S; De Luca F; Tassone P; Tagliaferri P
Clin Cancer Res; 2012 Feb; 18(3):850-7. PubMed ID: 22142823
[TBL] [Abstract][Full Text] [Related]
24. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).
Schmoll HJ; Cunningham D; Sobrero A; Karapetis CS; Rougier P; Koski SL; Kocakova I; Bondarenko I; Bodoky G; Mainwaring P; Salazar R; Barker P; Mookerjee B; Robertson J; Van Cutsem E
J Clin Oncol; 2012 Oct; 30(29):3588-95. PubMed ID: 22965961
[TBL] [Abstract][Full Text] [Related]
25. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
Peeters M; Price TJ; Cervantes A; Sobrero AF; Ducreux M; Hotko Y; André T; Chan E; Lordick F; Punt CJ; Strickland AH; Wilson G; Ciuleanu TE; Roman L; Van Cutsem E; Tzekova V; Collins S; Oliner KS; Rong A; Gansert J
J Clin Oncol; 2010 Nov; 28(31):4706-13. PubMed ID: 20921462
[TBL] [Abstract][Full Text] [Related]
26. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY
Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090
[TBL] [Abstract][Full Text] [Related]
27. [Correlation analysis between abundance of K-ras mutation in plasma free DNA and its correlation with clinical outcome and prognosis in patients with metastatic colorectal cancer].
Bai YQ; Liu XJ; Wang Y; Ge FJ; Zhao CH; Fu YL; Lin L; Xu JM
Zhonghua Zhong Liu Za Zhi; 2013 Sep; 35(9):666-71. PubMed ID: 24332053
[TBL] [Abstract][Full Text] [Related]
28. Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab.
Piessevaux H; Buyse M; Schlichting M; Van Cutsem E; Bokemeyer C; Heeger S; Tejpar S
J Clin Oncol; 2013 Oct; 31(30):3764-75. PubMed ID: 24043732
[TBL] [Abstract][Full Text] [Related]
29. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
Hegewisch-Becker S; Graeven U; Lerchenmüller CA; Killing B; Depenbusch R; Steffens CC; Al-Batran SE; Lange T; Dietrich G; Stoehlmacher J; Tannapfel A; Reinacher-Schick A; Quidde J; Trarbach T; Hinke A; Schmoll HJ; Arnold D
Lancet Oncol; 2015 Oct; 16(13):1355-69. PubMed ID: 26361971
[TBL] [Abstract][Full Text] [Related]
30. CA19-9 level as a prognostic and predictive factor of bevacizumab efficacy in metastatic colorectal cancer patients undergoing oxaliplatin-based chemotherapy.
Narita Y; Taniguchi H; Komori A; Nitta S; Yamaguchi K; Kondo C; Nomura M; Kadowaki S; Takahari D; Ura T; Andoh M; Muro K
Cancer Chemother Pharmacol; 2014 Feb; 73(2):409-16. PubMed ID: 24322376
[TBL] [Abstract][Full Text] [Related]
31. Retrospective study as first-line chemotherapy combined anti-VEGF antibody with fluoropyrimidine for frail patients with unresectable or metastatic colorectal cancer.
Yoshida M; Goto M; Kii T; Nishitani H; Kawabe S; Kuwakado S; Asaishi K; Miyamoto T; Higuchi K
Digestion; 2013; 87(1):59-64. PubMed ID: 23343971
[TBL] [Abstract][Full Text] [Related]
32. SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer.
Hecht JR; Cohn A; Dakhil S; Saleh M; Piperdi B; Cline-Burkhardt M; Tian Y; Go WY
Clin Colorectal Cancer; 2015 Jun; 14(2):72-80. PubMed ID: 25982297
[TBL] [Abstract][Full Text] [Related]
33. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
Heinemann V; von Weikersthal LF; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Hielscher J; Scholz M; Müller S; Link H; Niederle N; Rost A; Höffkes HG; Moehler M; Lindig RU; Modest DP; Rossius L; Kirchner T; Jung A; Stintzing S
Lancet Oncol; 2014 Sep; 15(10):1065-75. PubMed ID: 25088940
[TBL] [Abstract][Full Text] [Related]
34. Secondary treatment and predictive factors for second-line chemotherapy after first-line oxaliplatin-based therapy in metastatic colorectal cancer.
Sørbye H; Berglund A; Tveit KM; Ogreid D; Wanderås EH; Wentzel-Larsen T; Dahl O; Glimelius B
Acta Oncol; 2007; 46(7):982-8. PubMed ID: 17917829
[TBL] [Abstract][Full Text] [Related]
35. Phase II study of interleukin-2 and 13-cis-retinoic acid as maintenance therapy in metastatic colorectal cancer.
Recchia F; Saggio G; Cesta A; Candeloro G; Di Blasio A; Amiconi G; Lombardo M; Nuzzo A; Lalli A; Alesse E; Necozione S; Rea S
Cancer Immunol Immunother; 2007 May; 56(5):699-708. PubMed ID: 16955297
[TBL] [Abstract][Full Text] [Related]
36. Prognostic and predictive significance of long interspersed nucleotide element-1 methylation in advanced-stage colorectal cancer.
Kaneko M; Kotake M; Bando H; Yamada T; Takemura H; Minamoto T
BMC Cancer; 2016 Dec; 16(1):945. PubMed ID: 27955637
[TBL] [Abstract][Full Text] [Related]
37. Predictive value of pretreatment lymphocyte count in stage II colorectal cancer and in high-risk patients treated with adjuvant chemotherapy.
Liang L; Zhu J; Jia H; Huang L; Li D; Li Q; Li X
Oncotarget; 2016 Jan; 7(1):1014-28. PubMed ID: 26510910
[TBL] [Abstract][Full Text] [Related]
38. [Change of Blood Neutrophil-to-Lymphocyte Ratio Predicts Survival in Patients with Metastatic Colorectal Cancer].
Muneoka K; Shirai Y; Sasaki M; Sakata J; Kanda J; Wakabayashi H; Wakai T
Gan To Kagaku Ryoho; 2017 Apr; 44(4):313-317. PubMed ID: 28428512
[TBL] [Abstract][Full Text] [Related]
39. Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study.
Bennouna J; Borg C; Delord JP; Husseini F; Trillet-Lenoir V; Faroux R; François E; Ychou M; Goldwasser F; Bouché O; Senellart H; Kraemer S; Douillard JY
Clin Colorectal Cancer; 2012 Mar; 11(1):38-44. PubMed ID: 21803002
[TBL] [Abstract][Full Text] [Related]
40. PET scans as a predictive marker of survival in advanced colorectal cancer.
Choi M; Kollepara SL; Heilbrun LK; Smith D; Shields AF; Philip PA
Clin Colorectal Cancer; 2015 Mar; 14(1):35-40. PubMed ID: 25481195
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
